Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.52 USD
Change Today +0.20 / 8.62%
Volume 427.0K
MBVX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

mabvax therapeutics holdings (MBVX) Snapshot

Open
$2.43
Previous Close
$2.32
Day High
$2.57
Day Low
$2.29
52 Week High
09/10/14 - $15.00
52 Week Low
02/26/15 - $0.83
Market Cap
58.7M
Average Volume 10 Days
127.3K
EPS TTM
$-13.07
Shares Outstanding
23.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MABVAX THERAPEUTICS HOLDINGS (MBVX)

Related News

No related news articles were found.

mabvax therapeutics holdings (MBVX) Related Businessweek News

No Related Businessweek News Found

mabvax therapeutics holdings (MBVX) Details

MabVax Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of proprietary human monoclonal antibody products and vaccines for the diagnosis and treatment of various cancers. It has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company generates its pipeline of antibody-based product candidates from patients who have been vaccinated with propriety vaccines licensed from Memorial Sloan-Kettering Cancer Center (MSKCC). Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials; and a vaccine to address the orphan disease neuroblastoma has completed an initial Phase I trial at MSKCC, as well as completed an additional Phase I vaccine clinical trials in melanoma, ovarian cancer, breast cancer, and small cell lung cancer. The company’s product candidates include 5B1 antibody program, 5B1 imaging program, and 5B1 antibody drug conjugate, which target antigens over expressed on metastatic pancreatic, colon, stomach, ovarian, breast, and small cell lung cancers. It also develops follow-on antibody products, including 1B7 and 31F9 antibody programs to the antigen GD2, which is over expressed on sarcoma, melanoma, and neuroblastoma. The company has collaboration agreement with Heidelberg Pharma GmbH and MSKCC. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

12 Employees
Last Reported Date: 04/2/15
Founded in 2006

mabvax therapeutics holdings (MBVX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $322.2K
Chief Financial Officer
Total Annual Compensation: $190.1K
Vice President of Product Development and Ope...
Total Annual Compensation: $91.0K
Vice President of Antibody Discovery
Total Annual Compensation: $208.6K
Compensation as of Fiscal Year 2014.

mabvax therapeutics holdings (MBVX) Key Developments

MabVax Therapeutics Holdings, Inc. Presents at BIO International Convention 2015, Jun-17-2015 09:45 AM

MabVax Therapeutics Holdings, Inc. Presents at BIO International Convention 2015, Jun-17-2015 09:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: John David Hansen, Chairman, Chief Executive Officer and President.

MabVax Therapeutics Holdings, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

MabVax Therapeutics Holdings, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported grant revenues of $239,539 against $94,900 a year ago. Loss from operations was $2,466,943 against $972,659 a year ago. Net loss was $2,447,320 against $972,898 a year ago. Net loss allocable to common stockholders was $20,393,475 or $6.25 per basic and diluted share against $3,219,742 or $12.67 per basic and diluted share a year ago.

MabVax Therapeutics Holdings, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 01:30 PM

MabVax Therapeutics Holdings, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 01:30 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: John David Hansen, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBVX:US $2.52 USD +0.20

MBVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBVX.
View Industry Companies
 

Industry Analysis

MBVX

Industry Average

Valuation MBVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.5x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 107.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MABVAX THERAPEUTICS HOLDINGS, please visit www.mabvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.